• Ziopharm Oncology Inc., of Boston, said it intends to commence an underwritten public offering of $50 million shares of its common stock. J.P. Morgan Securities LLC will act as sole book-running manager for the proposed offering and the company intends to grant the underwriters a 30-day option to purchase up to $7.5 million of additional shares.